Last reviewed · How we verify

NCT06769867

(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction

Not yet recruiting NA Last updated 18 March 2025
What this trial tests

NA trial testing PS-3D-DSA in Cerebrovascular Disease in 134 participants. Not yet recruiting.

Timeline
15 April 2025
Primary endpoint
31 May 2025
31 May 2025

Quick facts

Lead sponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationnon randomized
Designcrossover
Maskingtriple
Primary purposediagnostic
Enrollment134
Start date15 April 2025
Primary completion31 May 2025
Estimated completion31 May 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

18 and older, any sex, with Cerebrovascular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

If the participants agree to participate in this study, the participants will undergo two scans (classic 3D-DSA and PS-3D-DSA assisted scan) to compare the imaging effects of both. After the procedure, the investigators will record the radiation exposure and collect DSA images.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cerebrovascular Disease

Currently open trials in the same condition.

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06769867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing